These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 33478428

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS, TB Trials Consortium iAdhere Study Team.
    Ann Intern Med; 2017 Nov 21; 167(10):689-697. PubMed ID: 29114781
    [Abstract] [Full Text] [Related]

  • 3. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK, Sharma A, Kadhiravan T, Tharyan P.
    Cochrane Database Syst Rev; 2013 Jul 05; 2013(7):CD007545. PubMed ID: 23828580
    [Abstract] [Full Text] [Related]

  • 4. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM.
    Medicine (Baltimore); 2016 Aug 05; 95(34):e4126. PubMed ID: 27559940
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, Trauer JM, McBryde ES.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):218-227. PubMed ID: 30295760
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR, International Maternal Pediatric and Adolescents AIDS Clinical Trials Group, Tuberculosis Trials Consortium.
    JAMA Pediatr; 2015 Mar 01; 169(3):247-55. PubMed ID: 25580725
    [Abstract] [Full Text] [Related]

  • 10. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, Ruan SY, Wang JY, Wang JT.
    Tuberculosis (Edinb); 2018 Jul 01; 111():121-126. PubMed ID: 30029896
    [Abstract] [Full Text] [Related]

  • 11. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, Ho CS.
    Clin Infect Dis; 2017 Oct 01; 65(7):1085-1093. PubMed ID: 28575208
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM.
    Ann Pharmacother; 2020 May 01; 54(5):457-463. PubMed ID: 31729245
    [Abstract] [Full Text] [Related]

  • 14. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, Lee NY, Liou BH, Tang HJ, Lee MH, Wang NC, Chen TC, Hii IM, Huang SH, Lin CY, Tsai CS, Cheng CY, Hung CC, Taiwan HIV Study Group .
    Clin Infect Dis; 2024 May 15; 78(5):1295-1303. PubMed ID: 38051646
    [Abstract] [Full Text] [Related]

  • 15. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG.
    Pharmacoepidemiol Drug Saf; 2018 Jun 15; 27(6):557-566. PubMed ID: 29573031
    [Abstract] [Full Text] [Related]

  • 16. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.
    Am J Respir Crit Care Med; 2006 Apr 15; 173(8):922-6. PubMed ID: 16474028
    [Abstract] [Full Text] [Related]

  • 17. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM, Jalees M, Lam C, Burzynski J.
    Int J Tuberc Lung Dis; 2018 Nov 01; 22(11):1344-1349. PubMed ID: 30355415
    [Abstract] [Full Text] [Related]

  • 18. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL.
    Am J Respir Crit Care Med; 2011 Sep 15; 184(6):732-7. PubMed ID: 21659613
    [Abstract] [Full Text] [Related]

  • 19. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL, Lee MR, Lee CH, Cheng MH, Lu PL, Sheu CC, Wang JY, Chong IW, Yang JM.
    Clin Microbiol Infect; 2024 Nov 15; 30(11):1410-1417. PubMed ID: 38996972
    [Abstract] [Full Text] [Related]

  • 20. Treatment of latent tuberculosis infection.
    Parekh MJ, Schluger NW.
    Ther Adv Respir Dis; 2013 Dec 15; 7(6):351-6. PubMed ID: 24056289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.